PK modeling in BE [NCA / SHAM]

posted by mittyri – Russia, 2020-07-19 00:24 (274 d 10:31 ago) – Posting: # 21744
Views: 1,531

Hi Helmut,

» However, last year at the 10th American Conference on Pharmacometrics (20–23 October, Orlando) she gave a presentation “Evaluation of Model Based BioEquivalence (MBBE) statistical approaches for sparse designs PK studies” with a whoopy mean (!) Type I Error of 7.6%. :-(

Are you referring to this one?
Stan approach is a bit better, but still questionable

Kind regards,
Mittyri

Complete thread:

Activity
 Admin contact
21,419 posts in 4,475 threads, 1,510 registered users;
online 12 (0 registered, 12 guests [including 2 identified bots]).
Forum time: Monday 10:56 CEST (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5